Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical Prospects.
Acute kidney injury (AKI) is one of the most common complications in critically ill patients, resulting in high morbidity and mortality. AKI usually occurs after major surgery, severe infection or drug-induced nephrotoxicity and is associated with prolonged hospital stays, increased costs and adverse clinical outcomes. The diagnosis of AKI is currently based on decreased glomerular filtration rate (GFR) and urine output, and increased serum creatinine. Novel biomarkers are required for early identification of patients with AKI to allow timely therapy and improve patient outcomes. With the advent of proteomics and genomics techniques, a vast array of biomarkers are now available in clinical practice.
['Huang|Hong-Feng|HF|', 'Zhou|Jing-Yi|JY|', 'Chen|Jiang-Hua|JH|']
D058186:Acute Kidney Injury D015415:Biomarkers D003404:Creatinine D016638:Critical Illness D055316:Cystatin C D042241:Early Diagnosis D050556:Fatty Acid-Binding Proteins D005919:Glomerular Filtration Rate D000072596:Hepatitis A Virus Cellular Receptor 1 D006801:Humans D020382:Interleukin-18 D000071068:Lipocalin-2 D011237:Predictive Value of Tests D000074083:Sodium-Hydrogen Exchanger 3 D017923:Sodium-Hydrogen Exchangers D016482:Urinalysis
biomarkers Acute kidney injury IL-18 KIM-1 L-FABP NGAL NHE-3 cystatin C